No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Biocoat Launches Coating Equipment Business Unit; Completes Full-Service Hydrophilic Coating Offering

Editor: What To Know

  • Biocoat’s coating systems will be available in either Thermal heat or Ultraviolet (UV) cure systems and is available in two models, the semi-automated Compact system, that offers an annual production of ~25,000 units per year per shift and the One Touch automated system that can coat ~75,000-100,000 units per year per shift.
  • The addition of coating equipment now positions Biocoat as one of the only companies that can offer a complete, full-service solution for medical devices that require a hydrophilic coating.
  • The EMERSE hydrophilic dip coating system is specifically designed and manufactured to meet the rigorous requirements that are encountered when coating products in the medical device, pharmaceutical, biotechnology and life science industries.

Biocoat Inc. announced its expansion into the design, development and delivery of hydrophilic dip coating equipment.  Biocoat’s new equipment line is called EMERSE and offers companies who require an in-house dip coating system to coat their medical devices and complete the production process.

The addition of coating equipment now positions Biocoat as one of the only companies that can offer a complete, full-service solution for medical devices that require a hydrophilic coating. The EMERSE hydrophilic dip coating system is specifically designed and manufactured to meet the rigorous requirements that are encountered when coating products in the medical device, pharmaceutical, biotechnology and life science industries. Biocoat’s coating systems will be available in either Thermal heat or Ultraviolet (UV) cure systems and is available in two models, the semi-automated Compact system, that offers an annual production of ~25,000 units per year per shift and the One Touch automated system that can coat ~75,000-100,000 units per year per shift.

“The addition of coating equipment fulfills our strategic vision of making Biocoat the premier full-service coatings company to partner with for medical device companies.” said Jim Moran, President, and CEO, Biocoat. “Our coating systems will be automated and fully compatible for use on either our industry leading HYDAK® coatings or any other coatings in the market. Our aim is to work closely with our customers to provide the highest level of service available, while ensuring that we deliver the equipment on-time and on-budget, every time.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy